National Cancer Institute - U.S. National Institutes of Health - www.cancer.govSkip navigationNational Cancer Institute - U.S. National Institutes of Health - www.cancer.govClinical Trials at NIH - Be part of the cure
National Cancer Institute - U.S. National Institutes of Health - www.cancer.gov
Clinical Trials at NIH Home

Clinical Trials by Cancer Site

Leukemia

Leukemia is a cancer of the bone marrow and blood that affects both adults and children. Leukemia cells are abnormal blood cells that crowd out normal blood cells, making it hard for the normal blood cells to do their work.

Leukemia is either chronic (which mean it usually gets worse slowly) or acute (which means it usually gets worse quickly).

There are four main types of leukemia:

  • Chronic lymphocytic leukemia (CLL): usually grows slowly and is most often diagnosed in people older than age 55
  • Chronic myeloid leukemia (CML): usually grows slowly and mainly affects adults
  • Acute lymphocytic (lymphoblastic) leukemia (ALL): grows quickly and is the most common type of leukemia in young children
  • Acute myeloid leukemia (AML): grows quickly and affects both adults and children

It is estimated that 48,610* people in the United States will be newly diagnosed with leukemia in 2013.

Treatment options for leukemia vary depending on the type of leukemia, stage of the disease, previous treatment, and other medical conditions. Talk with your doctor about what treatment options may be available for you.

*American Cancer Society. Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2013

Leukemia Clinical Trials

The NCI Center for Cancer Research (CCR) conducts clinical trials at the NIH Clinical Center in Bethesda, Maryland. CCR is currently conducting the following trials for patients with leukemia. Click on the trials below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the principal investigators and their staff directly. For information on a particular trial or to discuss a screening visit, contact a member of the research team listed on the trial’s summary.

If you need further assistance, call our toll-free number at 1-888-NCI-1937 (1-888-624-1937) to be connected to a referral coordinator appropriate for your diagnosis.


  
Trial and Protocol Number
Leukemia
Phase II
KW 0761 or Investigator’s Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
NCI-13-C-0069, NCT01626664

Principal Investigator:Referral Contact:
Kevin ConlonTat’Yana Worthy
301-496-7417301-496-0499
worthyt@mail.nih.gov
Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL)
NCI-13-C-0006, NCT01712659

Principal Investigator:Referral Contact:
Kevin ConlonTat’Yana Worthy
301-496-7417301-496-0499
worthyt@mail.nih.gov
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
NCI-10-C-0025, NCT01059786

Principal Investigator:Referral Contact:
Robert J. KreitmanElizabeth Maestri
301-496-6947301-402-5633
maestrie@mail.nih.gov
Phase II Trial of LMB-2, Fludarabine, and Cyclophosphamide for Adult T-Cell Leukemia
NCI-09-C-0025, NCT00924170

Principal Investigator:Referral Contact:
Robert J. KreitmanNatasha Kormanik
301-496-6947301-496-9458
kormanikn@mail.nih.gov
Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease
NCI-09-C-0005, NCT00923013

Principal Investigator:Referral Contact:
Robert J. KreitmanNatasha Kormanik
301-496-6947301-496-9458
kormanikn@mail.nih.gov
Phase II Study of LMB-2 Immunotoxin in Patients With Recurrent or Refractory CD25-Positive Hairy Cell Leukemia
NCI-06-C-0150, NCT00321555

Principal Investigator:Referral Contact:
Robert J. KreitmanNatasha Kormanik
301-496-6947301-496-9458
kormanikn@mail.nih.gov
Phase I
A Phase I, Multicenter, Dose-Escalation Study of CAT-8015 in Patients With Relapsed or Refractory Hairy Cell Leukemia
NCI-07-C-0130, NCT00462189

Principal Investigator:Referral Contact:
Robert J. KreitmanNatasha Kormanik
301-496-6947301-496-9458
kormanikn@mail.nih.gov


  
Trial and Protocol Number
Graft-Versus-Host Disease
Phase II
A Randomized Phase II Single-Center Study of Pomalidomide for Chronic Graft-Versus-Host Disease (GvHD)
NCI-12-C-0197, NCT01688466

Principal Investigator:Referral Contact:
Steven Z. PavleticKristen Cole
301-402-4899301-451-6569
colekr@mail.nih.gov
A Randomized Double-Blind Pilot Study of Topical Clobetasol 0.05% Oral Rinse for Oral Chronic Graft-Versus-Host Disease
NCI-12-C-0068, NCT01557517

Principal Investigator:Referral Contact:
Steven Z. PavleticKristen Cole
301-402-4899301-451-6569
colekr@mail.nih.gov
No Phase
Prospective Assessment of Clinical and Biological Factors Determining Outcomes in Patients With Chronic Graft-Versus-Host Disease (GVHD)
NCI-04-C-0281, NCT00092235

Principal Investigator:Referral Contact:
Steven Z. PavleticZetta Blacklock
301-402-4899301-594-2056
bblacklock@mail.nih.gov


  
Trial and Protocol Number
Hematologic/Blood Cancers
Phase II
Multi-institutional Prospective Pilot Study of Lupron to Enhance Lymphocyte Immune Reconstitution Following Allogeneic Bone Marrow Transplantation in Post-pubertal Children and Adults With Molecular Imaging Evaluation
NCI-11-C-0136, NCT01338987

Principal Investigator:Referral Contact:
Kirsten M. WilliamsZetta Blacklock
301-435-6456301-594-2056
bblacklock@mail.nih.gov
Allogeneic HSCT Without Preparative Chemotherapy or With Low-Intensity Preparative Chemotherapy Using Sirolimus and Sirolimus Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome
NCI-04-C-0055, NCT00074490

Principal Investigator:Referral Contact:
Daniel H. FowlerZetta Blacklock
301-435-8641301-594-2056
bblacklock@mail.nih.gov
Phase I/II
Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation
NCI-09-C-0224, NCT00984165

Principal Investigator:Referral Contact:
Nancy M. HardyZetta Blacklock
301-451-1406301-594-2056
bblacklock@mail.nih.gov
Assessment of the Safety and Feasibility of Administering T cells Expressing an anti-CD19 Chimeric Antigen Receptor to Patients With B-cell Lymphoma or Leukemia
NCI-09-C-0082, NCT00924326

Principal Investigator:Referral Contact:
Steven A. RosenbergJune A. Kryk
1-866-820-4505 (Toll Free)1-866-820-4505
(Toll Free)
ncisbirc@mail.nih.gov
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies
NCI-08-C-0051, NCT00923910

Principal Investigator:Referral Contact:
Alan S. WaynePediatric Oncology
301-496-4256301-496-4256
1-877-624-4878 (Toll free)

Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-Matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders
NCI-07-C-0195, NCT00520130

Principal Investigator:Referral Contact:
Steven Z. PavleticZetta Blacklock
301-402-4899301-594-2056
bblacklock@mail.nih.gov
Phase I
Study of the Biology and Natural History of Disease Outcomes in Patients Treated With Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
NCI-11-C-0125, NCT01326728

Principal Investigator:Referral Contact:
Nancy M. HardyZetta Blacklock
301-451-1406301-594-2056
bblacklock@mail.nih.gov
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
NCI-10-C-0054, NCT01087294

Principal Investigator:Referral Contact:
James N. KochenderferZetta Blacklock
301-594-5340301-594-2056
bblacklock@mail.nih.gov
A Phase I, Multi-Center, Dose Escalation Study of CAT-8015 in Pediatric Patients With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin’s Lymphoma (NHL)
NCI-08-C-0123, NCT00659425

Principal Investigator:Referral Contact:
Alan S. WaynePediatric Oncology
301-496-4256301-496-4256
1-877-624-4878 (Toll free)

No Phase
Hematologic Malignancy Biology Study
NCI-04-C-0102, NCT00923442

Principal Investigator:Referral Contact:
Alan S. WaynePediatric Oncology
301-496-4256301-496-4256
1-877-624-4878 (Toll free)



  
Trial and Protocol Number
Pediatric Cancers
Phase I
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies
NCI-12-C-0112, NCT01593696

Principal Investigator:Referral Contact:
Alan S. WaynePediatric Oncology
301-496-4256301-496-4256
1-877-624-4878 (Toll free)



  
Trial and Protocol Number
Solid Tumor
Phase I
A Phase I and Pharmacokinetic Single-agent Study of Romidepsin in Patients With Lymphomas, Chronic Lymphocytic Leukemia, Select Solid Tumors, and Varying Degrees of Liver Dysfunction
NCI-12-C-0177, NCT01638533

Principal Investigator:Referral Contact:
Shivaani KummarJanelle Bingham
301-435-0517301-435-2715
jbingham@mail.nih.gov


Back to Top
Health and Human Services National Institutes of Health National Cancer Institute USA.gov